GlassScriptPhysician profile
Thomas Russ
NPI 1306869185
$6,803.14
in general payments reported to CMS, 2019-2025
19 companies · $194 in 2025
The $194 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $318 · 2020: $637 · 2021: $1,215 · 2022: $3,612 · 2023: $551 · 2024: $276 · 2025: $194.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,021.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,020.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $3,793.69 | 2019-2025 | Jot Dx, Aveir, Merlin@Home |
| Medtronic, INC. | $1,251.02 | 2021-2025 | Onyx Frontier, Cobalt Dr Mri Surescan, Attain Command + Surevalve |
| Boston Scientific Corporation | $698.05 | 2020-2023 | Synergy, Comet |
| Amarin Pharma, INC. | $164.02 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $133.49 | 2021-2023 | Farxiga |
| Merck Sharp & Dohme LLC | $118.66 | 2021-2024 | Verquvo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $99.79 | 2022-2023 | Jardiance |
| Philips North America LLC | $82.96 | 2022-2024 | (Cm9) Amb Mon & Diag Und |
| Alnylam Pharmaceuticals INC. | $69.94 | 2023-2025 | Amvuttra, Onpattro |
| Kiniksa Pharmaceuticals, LTD. | $64.68 | 2021-2023 | Arcalyst |
| Novartis Pharmaceuticals Corporation | $59.10 | 2019-2020 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $44.04 | 2025 | Lifevest |
| Medtronic Vascular, INC. | $43.51 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $42.95 | 2025 | |
| Cardinal Health 200 LLC | $38.77 | 2020 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $30.26 | 2020 | |
| Shockwave Medical, INC | $29.07 | 2022 | |
| Edwards Lifesciences Corporation | $27.89 | 2025 | Sapien 3 Ultra Resilia |
| Bardy Diagnostics, INC. | $11.25 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Russ listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.